{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T23:06:15Z","timestamp":1769641575308,"version":"3.49.0"},"reference-count":23,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T00:00:00Z","timestamp":1353456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u00a0<\/jats:bold>Although long\u2010term cyclosporine administration may induce toxic effects, it may be the only option for the treatment of severe psoriasis. The objective of the present study was to retrospectively evaluate efficacy and safety of long\u2010term cyclosporine treatment in a cohort of patients affected with moderate to severe psoriasis, recalcitrant or unresponsive to other treatments. Possible risk factors predicting an intolerance to cyclosporine were also investigated.<\/jats:p><jats:p><jats:bold>Materials and methods\u00a0<\/jats:bold>Data were collected on psoriatic patients treated with cyclosporine for at least six\u2003months at our Psoriasis Outpatient Unit between January 2005 and September 2010. The primary measure for clinical efficacy was the PASI 75 response. Cyclosporine safety was assessed through the review of both laboratory tests and the adverse events registered during the treatment.<\/jats:p><jats:p><jats:bold>Results\u00a0<\/jats:bold>Twenty patients affected with plaque or erythrodermic psoriasis were evaluated. At Week 16, the PASI 75 response was achieved by 85% of patients. Adverse events occurred in eight patients (40%): four experienced an increase in serum creatinine levels to more than 30% of their pre\u2010treatment values and four developed hypertension. Among these patients, five discontinued cyclosporine. Side effects resolved after stopping treatment.<\/jats:p><jats:p><jats:bold>Conclusions\u00a0<\/jats:bold>Our findings suggest that long\u2010term cyclosporine regimen can be justified in severe psoriasis not responsive to other treatments. When cyclosporine administration is required, obesity, pre\u2010treatment controlled hypertension, increased age (&gt;70\u2003years), and metabolic syndrome should be taken into consideration, as a significant correlation with occurrence of cyclosporine\u2010induced side effects has been found.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2012.05571.x","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T18:46:48Z","timestamp":1353523608000},"page":"1512-1516","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients"],"prefix":"10.1111","volume":"51","author":[{"given":"Alessandro","family":"Borghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto Maria","family":"Bertoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Giari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarosa","family":"Virgili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,11,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1361.110"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta4400"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.027"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.017"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.063"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.112400"},{"key":"e_1_2_5_9_2","first-page":"218","article-title":"Cyclosporin in psoriasis: continuous monotherapy versus intermittent long\u2010term therapy","volume":"9","author":"Ozawa A","year":"1999","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80219-8"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90726-4"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02122.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0366-077X.2004.05949.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb02935.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archderm.1996.03890300039008","article-title":"Long\u2010term safety of cyclosporine in the treatment of psoriasis","volume":"132","author":"Grossman RM","year":"1996","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630510011829"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/039463201002300137"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198905000-00012"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.15.1598"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate\u2010to\u2010severe chronic plaque psoriasis to low\u2010dose cyclosporine therapy: a randomised, controlled, investigator\u2010blinded clinical trial","volume":"88","author":"Gisondi P","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000156599"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206183262502"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)65772-3"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2012.05571.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2012.05571.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T09:24:34Z","timestamp":1745227474000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2012.05571.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,21]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1365-4632.2012.05571.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2012.05571.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,21]]},"assertion":[{"value":"2012-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}